Connect Biopharma Holdings (CNTB) Receivables (2023 - 2026)

Connect Biopharma Holdings (CNTB) has reported Receivables for 4 consecutive years, with $32000.0 the latest figure, recorded in Q1 2026.

• Quarterly Receivables fell 81.71% year-over-year to $32000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32000.0 (down 81.71% YoY) and the FY2025 annual result came in at $161000.0, down 84.68% from the prior year.
• Receivables slipped to $32000.0 in Q1 2026 per CNTB's latest filing, from $161000.0 in the prior quarter.
• Over the last five years, Receivables for CNTB reached as high as $3.9 million in Q2 2024 and fell as low as $32000.0 in Q1 2026.
• A 4-year average of $654375.0 and a median of $184000.0 in 2025 frame the typical range for Receivables.
• Annual changes were most pronounced in 2024 — Receivables fell 25.36% — and 2025, when it slumped 95.03%.
• Year by year, Receivables stood at $351000.0 in 2023, then declined by 25.36% to $262000.0 in 2024, then sank by 38.55% to $161000.0 in 2025, then tumbled by 80.12% to $32000.0 in 2026.
• According to Business Quant data, Receivables over the past three periods registered $32000.0, $161000.0, and $174000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.